
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+14
Oncopeptides is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. Pepaxti (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least...
Multiple myeloma,plasma cell myeloma,orphan drug,relapsed & relapsed-refractory multiple myeloma,anti-angiogenic,cytotoxicity,alkylation,peptidase targeting,efficacy studies,oncology,peptide conjugated alkylator,phase 1,phase 3,melflufen,rrmm,peptide-drug conjugate,melphalan flufenamide,phase 2,and emd
Oncopeptides ab (publ) operates in the Pharmaceutical manufacturing industry.
Oncopeptides ab (publ)'s revenue is 1m - 10m
Oncopeptides ab (publ) has 51 - 200 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.